Open-label	open-label	O	O
assessment	assessment	O	O
of	of	O	O
levofloxacin	levofloxacin	S_chemical	O
for	for	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
acute	acute	O	O
bacterial	bacterial	O	O
sinusitis	sinusitis	O	O
in	in	O	O
adults	adults	O	O
.	.	O	O

PURPOSE	purpose	O	O
:	:	O	O
To	to	O	O
evaluate	evaluate	O	O
the	the	O	O
efficacy	efficacy	O	O
and	and	O	O
safety	safety	O	O
of	of	O	O
levofloxacin	levofloxacin	S_chemical	O
(	(	O	O
500	500	O	O
mg	mg	O	O
orally	orally	O	O
once	once	O	O
daily	daily	O	O
for	for	O	O
10	10	O	O
to	to	O	O
14	14	O	O
days	days	O	O
)	)	O	O
in	in	O	O
treating	treating	O	O
adult	adult	O	O
outpatients	outpatients	O	O
with	with	O	O
acute	acute	O	O
bacterial	bacterial	O	O
sinusitis	sinusitis	O	O
.	.	O	O

PATIENTS	patients	O	O
AND	and	O	O
METHODS	methods	O	O
:	:	O	O
A	a	O	O
total	total	O	O
of	of	O	O
329	329	O	O
patients	patients	O	O
enrolled	enrolled	O	O
in	in	O	O
the	the	O	O
study	study	O	O
at	at	O	O
24	24	O	O
centers	centers	O	O
.	.	O	O

All	all	O	O
patients	patients	O	O
had	had	O	O
a	a	O	O
pre-therapy	pre-therapy	O	O
Gram	gram	O	O
's	's	O	O
stain	stain	O	O
and	and	O	O
culture	culture	O	O
of	of	O	O
sinus	sinus	O	O
exudate	exudate	O	O
obtained	obtained	O	O
by	by	O	O
antral	antral	O	O
puncture	puncture	O	O
or	or	O	O
nasal	nasal	O	O
endoscopy	endoscopy	O	O
.	.	O	O

Clinical	clinical	O	O
response	response	O	O
was	was	O	O
assessed	assessed	O	O
on	on	O	O
the	the	O	O
basis	basis	O	O
of	of	O	O
signs	signs	O	B_disease
and	and	O	I_disease
symptoms	symptoms	O	I_disease
and	and	O	O
sinus	sinus	O	O
radiograph	radiograph	O	O
or	or	O	O
computed	computed	O	O
tomography	tomography	O	O
results	results	O	O
.	.	O	O

Microbiologic	microbiologic	O	O
cure	cure	O	O
rates	rates	O	O
were	were	O	O
determined	determined	O	O
on	on	O	O
the	the	O	O
basis	basis	O	O
of	of	O	O
presumed	presumed	O	O
plus	plus	O	O
documented	documented	O	O
eradication	eradication	O	O
of	of	O	O
the	the	O	O
pre-therapy	pre-therapy	O	O
pathogen(s	pathogen(s	O	O
)	)	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
The	the	O	O
most	most	O	O
common	common	O	O
pathogens	pathogens	O	O
were	were	O	O
Haemophilus	haemophilus	O	O
influenzae	influenzae	O	O
,	,	O	O
Streptococcus	streptococcus	O	O
pneumoniae	pneumoniae	O	O
,	,	O	O
Staphylococcus	staphylococcus	O	O
aureus	aureus	O	O
,	,	O	O
and	and	O	O
Moraxella	moraxella	O	O
catarrhalis	catarrhalis	O	O
.	.	O	O

Of	of	O	O
300	300	O	O
clinically	clinically	O	O
evaluable	evaluable	O	O
patients	patients	O	O
,	,	O	O
175	175	O	O
(	(	O	O
58	58	O	O
%	%	O	O
)	)	O	O
were	were	O	O
cured	cured	O	O
and	and	O	O
90	90	O	O
(	(	O	O
30	30	O	O
%	%	O	O
)	)	O	O
were	were	O	O
improved	improved	O	O
at	at	O	O
the	the	O	O
post-therapy	post-therapy	O	O
evaluation	evaluation	O	O
,	,	O	O
resulting	resulting	O	O
in	in	O	O
a	a	O	O
clinical	clinical	O	O
success	success	O	O
rate	rate	O	O
of	of	O	O
88	88	O	O
%	%	O	O
.	.	O	O

Thirty-five	thirty-five	O	O
patients	patients	O	O
(	(	O	O
12	12	O	O
%	%	O	O
)	)	O	O
clinically	clinically	O	O
failed	failed	O	O
treatment	treatment	O	O
.	.	O	O

The	the	O	O
microbiologic	microbiologic	O	O
eradication	eradication	O	O
rate	rate	O	O
(	(	O	O
presumed	presumed	O	O
plus	plus	O	O
documented	documented	O	O
)	)	O	O
among	among	O	O
138	138	O	O
microbiologically	microbiologically	O	O
evaluable	evaluable	O	O
patients	patients	O	O
was	was	O	O
92	92	O	O
%	%	O	O
.	.	O	O

Microbiologic	microbiologic	O	O
eradication	eradication	O	O
rates	rates	O	O
(	(	O	O
presumed	presumed	O	O
plus	plus	O	O
documented	documented	O	O
)	)	O	O
of	of	O	O
the	the	O	O
most	most	O	O
common	common	O	O
pathogens	pathogens	O	O
ranged	ranged	O	O
from	from	O	O
93	93	O	O
%	%	O	O
(	(	O	O
M.	m.	O	O
catarrhalis	catarrhalis	O	O
)	)	O	O
to	to	O	O
100	100	O	O
%	%	O	O
(	(	O	O
S.	s.	O	O
pneumoniae	pneumoniae	O	O
)	)	O	O
at	at	O	O
the	the	O	O
post-therapy	post-therapy	O	O
visit	visit	O	O
.	.	O	O

All	all	O	O
but	but	O	O
one	one	O	O
of	of	O	O
the	the	O	O
265	265	O	O
patients	patients	O	O
who	who	O	O
were	were	O	O
cured	cured	O	O
or	or	O	O
improved	improved	O	O
at	at	O	O
post-therapy	post-therapy	O	O
returned	returned	O	O
for	for	O	O
a	a	O	O
long-term	long-term	O	O
follow-up	follow-up	O	O
visit	visit	O	O
;	;	O	O
243	243	O	O
(	(	O	O
92	92	O	O
%	%	O	O
)	)	O	O
remained	remained	O	O
well	well	O	O
4	4	O	O
to	to	O	O
6	6	O	O
weeks	weeks	O	O
after	after	O	O
therapy	therapy	O	O
;	;	O	O
and	and	O	O
21	21	O	O
(	(	O	O
8	8	O	O
%	%	O	O
)	)	O	O
had	had	O	O
a	a	O	O
relapse	relapse	O	O
of	of	O	O
symptoms	symptoms	O	O
.	.	O	O

Adverse	adverse	O	O
events	events	O	O
considered	considered	O	O
to	to	O	O
be	be	O	O
related	related	O	O
to	to	O	O
levofloxacin	levofloxacin	S_chemical	O
administration	administration	O	O
were	were	O	O
reported	reported	O	O
by	by	O	O
29	29	O	O
patients	patients	O	O
(	(	O	O
9	9	O	O
%	%	O	O
)	)	O	O
.	.	O	O

The	the	O	O
most	most	O	O
common	common	O	O
drug-related	drug-related	O	O
adverse	adverse	O	O
events	events	O	O
were	were	O	O
diarrhea	diarrhea	O	S_disease
,	,	O	O
flatulence	flatulence	O	O
,	,	O	O
and	and	O	O
nausea	nausea	O	S_disease
;	;	O	O
most	most	O	O
adverse	adverse	O	O
events	events	O	O
were	were	O	O
mild	mild	O	O
to	to	O	O
moderate	moderate	O	O
in	in	O	O
severity	severity	O	O
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
The	the	O	O
results	results	O	O
of	of	O	O
this	this	O	O
study	study	O	O
indicate	indicate	O	O
that	that	O	O
levofloxacin	levofloxacin	S_chemical	O
500	500	O	O
mg	mg	O	O
once	once	O	O
daily	daily	O	O
is	is	O	O
an	an	O	O
effective	effective	O	O
and	and	O	O
safe	safe	O	O
treatment	treatment	O	O
for	for	O	O
acute	acute	O	O
bacterial	bacterial	O	O
sinusitis	sinusitis	O	O
.	.	O	O

